BTX BioTime, Inc. Common Stock

3.34
+0.04  (1%)
Previous Close 3.30
Open 3.40
Price To book 1.95
Market Cap 370.32M
Shares 110,875,000
Volume 516,866
Short Ratio 9.72
Av. Daily Volume 348,421

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 six and nine-month data released January 24, 2017. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017. Data Monitoring Committee (DMC) noted April 25 to continue trial as planned.
AST-OPC1 - SCiStar
Cervical spinal cord injury
Pivotal trial data due by mid-2017.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 2 second cohort underway. Interim data presented at May 8, 2017 at ARVO conference. Third cohort enrollment pending DSMB review due 2Q 2017.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
  2. BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
  3. Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1
  4. BioTime Presents Retinal Restoration Data at ARVO
  5. BioTime posts 1Q profit
  6. BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
  7. Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised
  8. Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View
  9. BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
  10. BioTime, Inc. : Undervalued relative to peers, but don’t ignore the other factors
  11. BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
  12. BioTime, Inc. is trading below its 50 day moving average : BTX-US : May 5, 2017
  13. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : May 2, 2017
  14. BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
  15. BioTime to Present Additional Data at Upcoming ARVO
  16. BioTime, Inc. is trading below its 50 day moving average : BTX-US : April 21, 2017
  17. BioTime, Inc. – Value Analysis (NYSE MKT:BTX) : April 20, 2017
  18. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : April 19, 2017
  19. ETFs with exposure to BioTime, Inc. : April 13, 2017
  20. BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging